Pharmanet Appoint New Chief Medical Officer
News Feb 21, 2011
In this position, he will be the senior medical representative for the Company and provide guidance to the Company's many physicians who are involved in designing and monitoring Phase I through Phase III clinical trials. He will also retain his current responsibilities heading PharmaNet's team of regulatory and pharmaceutical consultants which provide strategic drug development advice to clients.
"Excellence in pharmaceutical science and medicine is critical to the success of PharmaNet and its clients. We are therefore very pleased that Dr. Jeffrey Freitag, an accomplished internist and nephrologist, will be serving in the role of Chief Medical Officer," said Dr. Tom Newman, President of PharmaNet Development Group.
Dr. Freitag has worked in the pharmaceutical industry for over twenty-five years in a variety of positions including Vice President, Clinical Drug Development at The Liposome Company, Senior Vice President of Medical Affairs at PharmaNet and most recently as Vice President of Research & Development at Bone Care International before rejoining PharmaNet in 2006. Dr. Freitag is board certified in both Internal Medicine and Nephrology and has a strong academic, scientific and clinical background. He has extensive experience in providing medical and scientific direction and leadership to product development teams. He has also provided strategic clinical development consultation to clients in a variety of therapeutic areas including renal, pulmonary, cardiovascular, oncology and infectious disease therapeutic areas.
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE